Edap Tms (NASDAQ:EDAP) Share Price Passes Above 200 Day Moving Average – What’s Next?

Edap Tms S.A. (NASDAQ:EDAP)’s share price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $3.59 and traded as high as $4.47. Edap Tms shares last traded at $4.32, with a volume of 55,873 shares trading hands.

Analyst Ratings Changes

EDAP has been the subject of a number of research reports. Wall Street Zen lowered Edap Tms from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. HC Wainwright dropped their price target on Edap Tms from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $6.00.

Edap Tms Price Performance

The firm has a market capitalization of $161.91 million, a P/E ratio of -5.33 and a beta of -0.10. The firm has a 50 day moving average price of $3.74 and a 200-day moving average price of $3.59. The company has a current ratio of 1.34, a quick ratio of 0.99 and a debt-to-equity ratio of 1.79.

Edap Tms (NASDAQ:EDAP) last posted its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The company had revenue of $20.48 million during the quarter, compared to the consensus estimate of $19.46 million. Edap Tms had a negative net margin of 41.47% and a negative return on equity of 137.61%. On average, analysts expect that Edap Tms S.A. will post -0.82 earnings per share for the current year.

Insider Activity

In related news, Director Joshua Levine acquired 10,000 shares of the stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $4.22 per share, with a total value of $42,200.00. Following the purchase, the director directly owned 35,000 shares of the company’s stock, valued at approximately $147,700. This trade represents a 40.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 10.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Edap Tms

Institutional investors have recently modified their holdings of the stock. Rock Springs Capital Management LP lifted its stake in shares of Edap Tms by 1.3% in the 4th quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the medical equipment provider’s stock valued at $4,233,000 after purchasing an additional 16,500 shares during the last quarter. Kovack Advisors Inc. bought a new stake in shares of Edap Tms in the 4th quarter valued at approximately $53,000. Lido Advisors LLC bought a new stake in shares of Edap Tms in the 1st quarter valued at approximately $40,000. SmartHarvest Portfolios LLC bought a new stake in shares of Edap Tms in the 1st quarter valued at approximately $38,000. Finally, Flax Pond Capital LLC bought a new stake in shares of Edap Tms in the 4th quarter valued at approximately $2,623,000. 62.74% of the stock is owned by institutional investors.

Edap Tms Company Profile

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.